BiotechTube

Myfortic + Decortin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uveitis, Intermediate

Conditions

Uveitis, Intermediate

Trial Timeline

Mar 1, 2010 → Oct 1, 2015

NCT ID
NCT01092533

About Myfortic + Decortin

Myfortic + Decortin is a phase 3 stage product being developed by Novartis for Uveitis, Intermediate. The current trial status is completed. This product is registered under clinical trial identifier NCT01092533. Target conditions include Uveitis, Intermediate.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis, Intermediate were approved

Approved (3) Terminated (9) Active (8)
✅Ixekizumab Prefilled SyringeEli LillyApproved
✅AdalimumabAbbVieApproved
✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved
🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
🔄Baricitinib + AdalimumabEli LillyPhase 3
🔄adalimumabAbbViePhase 3
🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01092533Phase 3Completed

Competing Products

20 competing products in Uveitis, Intermediate

See all competitors
ProductCompanyStageHype Score
triamcinolone acetonide (Triesence®)Clearside BiomedicalPhase 1/2
22
4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
30
Baricitinib + AdalimumabEli LillyPhase 3
44
Ixekizumab Prefilled SyringeEli LillyApproved
39
adalimumabAbbViePhase 3
40
Adalimumab + Prednisone + PlaceboAbbViePhase 3
40
Adalimumab + Prednisone + PlaceboAbbViePhase 3
40
AdalimumabAbbVieApproved
43
FTY720 + Oral CorticosteroidNovartisPhase 2
27
AIN457NovartisPhase 3
32
MyforticNovartisPre-clinical
22
AIN457 + AIN457 + Placebo AIN457NovartisPhase 3
32
LFG316 + Conventional TherapyNovartisPhase 2
35
RanibizumabNovartisPhase 2
35
AIN457 + PlaceboNovartisPhase 3
32
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
AEB071NovartisPhase 2
35
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
AIN457 + AIN 457 + AIN457NovartisPhase 2
35
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32